Azitra, Inc. (NYSEAMERICAN:AZTR – Get Free Report) saw a significant decline in short interest in the month of October. As of October 15th, there was short interest totaling 112,293 shares, a decline of 53.4% from the September 30th total of 240,809 shares. Currently, 0.2% of the company’s shares are short sold. Based on an average daily volume of 667,182 shares, the short-interest ratio is presently 0.2 days.
Azitra Price Performance
AZTR stock traded up $0.01 during mid-day trading on Friday, reaching $0.77. 782,984 shares of the stock traded hands, compared to its average volume of 8,033,131. Azitra has a 52-week low of $0.52 and a 52-week high of $5.59. The stock’s fifty day moving average is $1.90 and its 200-day moving average is $1.96.
Azitra (NYSEAMERICAN:AZTR – Get Free Report) last released its earnings results on Wednesday, August 12th. The company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.15) by ($0.55). On average, analysts forecast that Azitra will post -2.00 earnings per share for the current year.
Azitra Company Profile
Azitra, Inc is a clinical-stage biotechnology company focused on developing microbiome-based therapies for dermatological conditions. The company combines microbiology, genetic engineering and computational tools to identify and develop targeted treatments intended to address diseases affecting the skin.
Azitra’s platform centers on engineered strains of beneficial skin bacteria and biologic compounds designed to deliver therapeutic proteins or otherwise influence the skin’s local environment.
Further Reading
- Five stocks we like better than Azitra
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
- Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?
- Oracle’s AI Spending Peak Is in Sight—Can the Stock Recover?
Receive News & Ratings for Azitra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azitra and related companies with MarketBeat.com's FREE daily email newsletter.
